Search Results

Tallac Therapeutics, Inc., a privately held clinical stage biopharmaceutical company pioneering the discovery and development of novel antibody-oligonucleotide conjugates, today announced the presentation of preclinical data demonstrating TAC-001 potentiates cancer vaccine efficacy and rejuvenates vaccine responses.

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, announced the first presentation of TAC-001 Phase 1 clinical safety and efficacy data in solid tumor patients.

Horizon Technology Finance Corporation announced it has provided a $15 million venture loan facility to Tallac Therapeutics, Inc., of which $5 million has been initially funded.

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the acceptance of two abstracts (related to TAC-001 and TAC-003) at the SITC 38th Annual Meeting in San Diego, CA, from November 3-5, 2023.

Tallac Therapeutics, Inc. today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.

Tallac Therapeutics, Inc. today announced that the Company presented data for two, first-in-class toll-like receptor 9 (TLR9) agonist antibody conjugates from its novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022).

Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service Agreements

Tallac Therapeutics, Inc. (“Tallac”), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors.

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to study TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors.